XML 48 R27.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Selected Quarterly Financial Data (unaudited) | 12 Months Ended
--- | ---
Dec. 31, 2017
Selected Quarterly Financial Information [Abstract] |
Selected Quarterly Financial Data (unaudited) | Selected Quarterly Financial Data (unaudited) Selected unaudited quarterly financial data for the years 2017 and 2016 are summarized below:
|  | 2017 |  | 2016
(Dollars in Millions Except Per Share Data) |  | First Quarter (1) |  | Second Quarter (2) |  | Third Quarter (3) |  | Fourth Quarter (4) |  | First Quarter (5) |  | Second Quarter (6) |  | Third Quarter (7) |  | Fourth Quarter (8)
Segment sales to customers |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consumer |  | $ | 3,228 |  |  | 3,478 |  |  | 3,356 |  |  | 3,540 |  |  | 3,195 |  |  | 3,419 |  |  | 3,261 |  |  | 3,432 |
Pharmaceutical |  | 8,245 |  |  | 8,635 |  |  | 9,695 |  |  | 9,681 |  |  | 8,178 |  |  | 8,654 |  |  | 8,400 |  |  | 8,232 |
Medical Devices |  | 6,293 |  |  | 6,726 |  |  | 6,599 |  |  | 6,974 |  |  | 6,109 |  |  | 6,409 |  |  | 6,159 |  |  | 6,442 |
Total sales |  | 17,766 |  |  | 18,839 |  |  | 19,650 |  |  | 20,195 |  |  | 17,482 |  |  | 18,482 |  |  | 17,820 |  |  | 18,106 |
Gross profit |  | 12,380 |  |  | 13,016 |  |  | 12,748 |  |  | 12,952 |  |  | 12,153 |  |  | 13,146 |  |  | 12,334 |  |  | 12,572 |
Earnings before provision for taxes on income |  | 5,575 |  |  | 4,748 |  |  | 4,790 |  |  | 2,560 |  |  | 5,294 |  |  | 4,904 |  |  | 5,281 |  |  | 4,324 |
Net earnings (loss) |  | 4,422 |  |  | 3,827 |  |  | 3,764 |  |  | (10,713 | ) |  | 4,457 |  |  | 3,997 |  |  | 4,272 |  |  | 3,814 |
Basic net earnings (loss) per share |  | $ | 1.63 |  |  | 1.42 |  |  | 1.40 |  |  | (3.99 | ) |  | 1.62 |  |  | 1.46 |  |  | 1.56 |  |  | 1.41 |
Diluted net earnings (loss) per share |  | $ | 1.61 |  |  | 1.40 |  |  | 1.37 |  |  | (3.99 | ) |  | 1.59 |  |  | 1.43 |  |  | 1.53 |  |  | 1.38 |
(1) | The first quarter of 2017 includes a restructuring charge of $121 million after-tax ($161 million before-tax) and an AMO acquisition related cost of $251 million after-tax ($38 million before-tax).
(2) | The second quarter of 2017 includes a net litigation expense of $352 million after-tax ($493 million before-tax), Actelion acquisition related costs of $199 million after-tax ($213 million before-tax) a restructuring charge of $101 million after-tax ($128 million before-tax) and an asset impairment charge of $125 million after-tax ($182 million before-tax).
(3) | The third quarter of 2017 includes a net litigation expense of $97 million after-tax ($118 million before-tax), Actelion acquisition related costs of $255 million after-tax ($367 million before-tax) and a restructuring charge of $136 million after-tax ($187 million before-tax).
(4) | The fourth quarter of 2017 includes a net litigation expense of $506 million after-tax ($645 million before-tax), Actelion acquisition related costs of $313 million after-tax ($217 million before-tax), a restructuring charge of $237 million after-tax ($284 million before-tax), an in-process research and development expense of $266 million after-tax ($408 million before-tax) and an after-tax benefit of $116 million related to the insulin pump business. Additionally, the fourth quarter of 2017 includes a provisional charge of $13.6 billion for recently enacted tax legislation.
(5) | The first quarter of 2016 includes a restructuring charge of $120 million after-tax ($137 million before-tax) and net litigation expense of $56 million after-tax ($66 million before-tax).
(6) | The second quarter of 2016 includes a restructuring charge of $97 million after-tax ($141 million before-tax) and net litigation expense of $493 million after-tax ($600 million before-tax).
(7) | The third quarter of 2016 includes a restructuring charge of $76 million after-tax ($109 million before-tax) and net litigation expense of $46 million after-tax ($55 million before-tax).
(8) | The fourth quarter of 2016 includes a restructuring charge of $251 million after-tax ($298 million before-tax) and net litigation expense of $80 million after-tax ($96 million before-tax).

X
- Definition The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -URI http://asc.fasb.org/topic&trid=2126967 + Details
Name: | us-gaap_QuarterlyFinancialInformationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SelectedQuarterlyFinancialInformationAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration